MyRBQM Portal has made its debut on the Azure Marketplace. This milestone allows biopharmaceutical companies to streamline and unify their approach to risk management by using the secure and reliable Azure cloud platform.
Discover how Decentralized Clinical Trials (DCTs) have the potential to reshape oncology care. Using our eyesON DCT Outlook, we reveal how patient demographics, broadband internet, and registered oncologists could drive DCT opportunities and potentially enhance cancer survivorship.
Be prepared for ICH E6(R3): turn guidelines into real-world action. In this post, we delve into the key updates and training gaps.
Unpacking the new ICH guidelines, E6(R3) and E8(R1), we illuminate their key elements, identify gaps, and compare the two in terms of their unity, differences, and complementarity.
Dive into the FDA's latest draft guidance on Decentralized Clinical Trials and the role of Risk-Based Quality Management. Learn how RBQM and centralized monitoring can elevate your clinical research efficiency and reliability.
Navigate your M&A journey confidently with Cyntegrity's MyRBQM Portal. Aspiring to hit your targets within 6-12 months? Discover how we can make it possible in R&D due diligence.
We're excited to announce the launch of Cyntegrity's new online learning platform, MyRBQM Academy. As a pioneer in providing intelligent RBQM technology solutions, we believe that education is the first step in transitioning to a new way of working in clinical research.
Discover how clinical data management in the US has transformed from data collection to a multi-faceted endeavor, driving breakthroughs in biomedical research, diagnostics, drug development, and vaccines. Learn from leading experts, including our Chief Scientific Officer, about the latest advancements and future prospects in this groundbreaking publication.
Clinical trials require a comprehensive approach to ensure quality and efficiency. Quality by Design, Risk-Based Monitoring, and Risk-Based Quality Management work together to achieve these goals, focusing on building quality into the trial process, targeting monitoring activities, and continuously improving trial quality.
This opinion piece by Keith Dorricott, MBB, addresses the challenges faced by the clinical trial industry in implementing QTLs and KRIs as required by ICH E6(R2). The article explores why KRIs have been easier to adopt than QTLs and wonders if the specific guidance provided by ICH E6(R2) is partly responsible.
